Fluciclovine Production Cost Reports

The report provides a detailed analysis essential for establishing a Fluciclovine production plant. It encompasses all critical aspects necessary for Fluciclovine production, including the cost of Fluciclovine production, Fluciclovine plant cost, Fluciclovine production costs, and the overall Fluciclovine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Fluciclovine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Fluciclovine is a radiopharmaceutical used mainly in medical imaging to help detect the return or spread of prostate cancer. It is commonly used as a radiotracer during PET scans, where it highlights cancer-affected tissues by being taken up more readily by cells with increased amino acid transport activity.

It is valued for identifying cancer activity even when PSA levels are low, giving doctors clearer information for planning treatment. It is also useful in follow-up care, as it helps track changes in cancer over time. Additionally, Fluciclovine is also studied in research settings to explore its usefulness in detecting other types of tumours, which makes it an importance tool in diagnostic imaging.

The demand for Fluciclovine is mainly led by its application as a radiotracer for PET imaging to detect recurrent or metastatic prostate cancer, which strongly supports its demand in the diagnostic and nuclear medicine sectors. Its application in highlighting cancer-affected tissues with high accuracy for patients who require precise monitoring after treatment further promotes its demand in hospitals and imaging centres.

In addition, advances in imaging technology, supplier reliability, adherence to sustainability and waste-management practices, and efficient logistics for short-lived isotopes also play a major role in shaping global demand for Fluciclovine. Industrial Fluciclovine procurement depends on factors such as the cost and availability of radioactive isotopes, compliance with radiation safety standards, and strict regulatory guidelines for radiopharmaceutical production.

Raw Material for Fluciclovine Production

According to the Fluciclovine production plant project report, the major raw materials for Fluciclovine production includes (S)-2-amino-3-(benzyloxycarbonyl)-2-spiro[cyclopropane-1,1′-cyclobutane]-carboxylic acid ethyl ester.

Production Process of Fluciclovine

The extensive Fluciclovine production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Fluciclovine begins with converting the spirocyclic starting material FLUC-001 ((S)-2-amino-3-(benzyloxycarbonyl)-2-spiro[cyclopropane-1,1′-cyclobutane]-carboxylic acid ethyl ester) into the corresponding hydrolysate by heating it with barium hydroxide. Then, this product is esterified with thionyl chloride and ethanol to form FLUC-003, which is further protected on the amine with a Boc group to give FLUC-004. Hydrogenation over Pd/C removes the benzyl group, which produces FLUC-005, and treatment with trifluoromethanesulfonic anhydride converts it into the activated triflate FLUC-006. Further, the intermediate undergoes radiofluorination with [18F]fluoride in the presence of Kryptofix 222, and the reaction mixture is then exposed to hydrochloric acid to remove protecting groups. The complete process results in the production of Fluciclovine F-18 as the final product.

Fluciclovine is an amino acid analogue used in diagnostic imaging. It exists in the form of a white to off-white solid that has no characteristic odour. The molecular formula of the compound is C5H8FNO2, and its molar mass is 133.12 g/mol. It is generally water-soluble due to its structural similarity to natural amino acids. It is advised to handle the compound with appropriate care, as it is a bioactive compound. Commercial ¹8F-fluciclovine injection (Axumin and equivalent formulations) is supplied as a clear, colourless solution of fluciclovine-18F in water for injection, buffered with trisodium citrate and citric acid to maintain stability. The pH of the solution is controlled between 4.0 and 7.5.